Rationale for Combining Acalabrutinib With Bendamustine and Rituximab in MCL

December 15, 2018
Tycel J. Phillips, MD

Tycel J. Phillips, MD, assistant professor at the University of Michigan Cancer Center, discusses an ongoing trial looking at acalabrutinib plus bendamustine and rituximab  in patients with treatment-naive or relapsed/refractory mantle cell lymphoma.

Tycel J. Phillips, MD, assistant professor at the University of Michigan Cancer Center, discusses an ongoing trial looking at acalabrutinib (Calquence) plus bendamustine and rituximab (Rituxan) in patients with treatment-naive or relapsed/refractory mantle cell lymphoma (MCL).

MCL is a rare subset of non-Hodgkin lymphoma and affects 5% to 6% of patients, Phillips says. It is common in patients over the age of 65, as well as in males. However, no official standard of care has been determined.